A phase I open-label dose escalation study of LJM716 administered intravenously in patients with squamous cell carcinoma of head and neck, or HER2 overexpressing metastatic breast cancer or gastric cancer

Trial Profile

A phase I open-label dose escalation study of LJM716 administered intravenously in patients with squamous cell carcinoma of head and neck, or HER2 overexpressing metastatic breast cancer or gastric cancer

Completed
Phase of Trial: Phase I

Latest Information Update: 13 Jun 2014

At a glance

  • Drugs Elgemtumab (Primary)
  • Indications Advanced breast cancer; Gastric cancer; Head and neck cancer; Oesophageal cancer
  • Focus Adverse reactions
  • Sponsors Novartis
  • Most Recent Events

    • 22 Apr 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 05 Feb 2014 Planned End Date changed from 1 Dec 2013 to 1 Jun 2014 as reported by ClinicalTrials.gov record.
    • 25 Oct 2013 Planned End Date changed from 1 Jun 2014 to 1 Dec 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top